Just Diagnosed

Dr. Karen Reckamp, City of Hope Cancer Center, provides her perspective on the likelihood that molecular oncology principles and targeted therapies will become more broadly applicable for patients with squamous and other lung cancer subtypes.

[powerpress]

Dr. Rosalyn Juergens, McMaster University, explains her approach to management of acquired resistance to targeted therapies in patients with a "driver mutation" and respond well initially to treatment.

[powerpress]

Dr. Karen Kelly of University of California, Davis, presents her current view on using molecular markers in early stage non-small cell lung cancer and explains the RADIANT study that she leads.

[powerpress]

Dr. Bob Doebele from the University of Colorado reviews which molecular markers have the strongest evidence to support routine testing, and which patients with advanced non-small cell lung cancer he favors molecular testing for. 

[powerpress]

Drs. Ross Camidge and Corey Langer offer their perspectives on the most encouraging emerging targets that could become valuable additions to our lung cancer treatment menu in the next several years.

[powerpress]

Dr. David Spigel, Sarah Cannon Cancer Center, reviews which patients with lung cancer he feels should undergo molecular testing, as well as describing the potential value of immediate, reflex testing for molecular targets.

[powerpress]

Dr. Lecia Sequist provides her thoughts on how molecular oncology can soon begin affecting treatment plans for a broader range of patients with lung cancer, including those with squamous NSCLC and other lung cancer histologies.

[powerpress]

Dr. Greg Riely from Memorial Sloan-Kettering notes how he feels molecular marker results for patients with earlier stage lung cancer can potentially be valuable.

[powerpress]

Dr. Geoffrey Oxnard, Dana Farber Cancer Institute, describes a wide range of options for best managing patients with advanced NSCLC who experience acquired resistance, the progression of cancer after a good initial response to a targeted therapy.

[powerpress]

Dr. Karen Reckamp, City of Hope Cancer Center, reviews her thought process in recommending a repeat biopsy at initial diagnosis or after progression for patients with advanced lung cancer.

[powerpress]